Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(1.02) by 11.76 percent. This is a 2180 percent decrease over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $28.00 million which missed the analyst consensus estimate of $36.54 million by 23.37 percent. This is a 80.69 percent decrease over sales of $145.00 million the same period last year.